Abstract
It has been suggested that treatment with adequate dose titration of pegvisomant, a GH antagonist, up to a maximum of 40 mg daily, can achieve IGF-1 normalisation in virtually all patients with acromegaly. On the other hand, temozolomide (TMZ), an alkylating cytostatic agent, has been reported to reduce pituitary tumour size and hormone hypersecretion in a small number of aggressive pituitary macroadenomas. In this paper we report the case of a patient resistant to very high doses of pegvisomant used in combination with somatostatin analogs (SSA) and to TMZ therapy. The patient, initially a 22 year-old man with an invasive GH-secreting pituitary macroadenoma (IGF-1, 371% upper limit of normal), had active acromegaly despite a repeat transsphenoidal surgery followed by radiotherapy and SSA (octreotide 800 μg sc daily) (IGF-1, 262% ULN). In combination with SSA, pegvisomant was started at 20 mg daily and doses were titrated up to 60 mg daily. IGF-1 was moderately reduced and stabilized at 200% ULN after 1 year of treatment. Serum pegvisomant level was 30,500 ng/l, the denaturalized GHBP concentration 1,120 pM and the endogenous GH level was 220 μg/l. Pegvisomant was stopped and TMZ therapy was given for 5 cycles. However, the patient reported an increase of acromegaly symptoms and the serum IGF-1 was raised to the same level prior to pegvisomant therapy. Consequently, pegvisomant was tried again with doses up to 100 mg daily finally resulting in normalisation of serum IGF-1 level and improvement of acromegaly symptoms and patient well-being. We conclude that in some patients with severe acromegaly refractory to multimodal therapy, biochemical control may be difficult to attain with conventional doses of pegvisomant or TMZ therapy.
References
Van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L et al (2001) Long term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754–1759
Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, Van der Lely AJ et al (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644–1646
Hagen C, Schroeder HD, Hansen S, Andersen M (2009) Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161:631–637
Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC et al (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphology findings. Hum Pathol 38:185–189
Syro LV et al (2009) Effect of Temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones 8(4):303–306
Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD (2009) Use of Temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64:773–774
Neff LM et al (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10(1):81–86
Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE et al (2006) Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65:552–553
Obari et al (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82–91
Bhayana et al (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90:6290–6295
Barlier et al (1999) Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 84:2759–2765
Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189–3202
Maiza JC, Caron P (2009) Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options. Ann Endocrinol (Paris) 70(Suppl 1):S12–S19 (French)
Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV et al (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115:261–262
Esteller M et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New Engl J Med 343:1350–1354
Bonert VS, Kennedy L, Petersenn S et al (2008) Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 93:3515–3518
Moore DJ, Adi Y, Connock MJ, Bayliss S (2009) Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord 9:20. doi:10.1186/1472-6823-9-20
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morin, E., Berthelet, F., Weisnagel, J. et al. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 15, 97–100 (2012). https://doi.org/10.1007/s11102-010-0232-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-010-0232-9